SCHEMBL2084664

SCHEMBL2084664

CC(C)(C)OC(=O)NC1(C(N)=O)CCS(=O)(=O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 1/20 0.36
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
CTSL P07711 1/20 0.33
MAPK1 P28482 1/20 0.33
APLNR P35414 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
GAA P10253 2/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
KDM4E B2RXH2 1/20 0.31
P2RX7 Q99572 1/20 0.31
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
CTSK P43235 1/20 0.31
POLB P06746 1/20 0.31
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2716648 0.87 KMT2A (0.36) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL2392486 0.87 KMT2A (0.38) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL2789711 0.86 GHSR (0.37) GHSRKMT2AMEN1CTSLMAPK1
SCHEMBL2087505 0.85 GAA (0.36) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL5427902 0.84 MAPT (0.37) GHSRKMT2AMEN1CTSLMAPK1
SCHEMBL4742076 0.83 KMT2A (0.36) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL2086150 0.81 KMT2A (0.38) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL14851186 0.80 P2RX7 (0.34) GHSRMAOAMAOBKMT2AMEN1
SCHEMBL12800025 0.80 GHSR (0.35) GHSRKMT2AMEN1CTSLMAPK1
SCHEMBL20054418 0.79 TSHR (0.37) GHSRMAOAMAOBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US disclosed
EP-2520577-B1 Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonists MITSUBISHI TANABE PHARMA CORP (JP) 2013-12-11 EP disclosed
EP-2520577-A1 Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists Mitsubishi Tanabe Pharma Corporation (JP) 2012-11-07 EP disclosed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US disclosed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR GHSR 277/4885MAOA 1665/4885MAOB 1169/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR GHSR 231/4885MAOA 1398/4885MAOB 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.